MAINTENENCE TREATMENT WITH MIRIKIZUMAB, A P19-DIRECTED IL-23 ANTIBODY: 52-WEEK RESULTS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITISGeert R. D'Haens,William J. Sandborn,Marc Ferrante,Bal R. Bhandari,Elina Berliba,Toshifumi Hibi,Jay Tuttle,Stuart Friedrich,Michael Durante,Vipin Arora,Brian G. Feagan,James CanavanGASTROENTEROLOGY(2019)引用 4|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要